<DOC>
	<DOC>NCT00090155</DOC>
	<brief_summary>The purpose of this study is to assess the safety and efficacy of 2 doses of an approved drug for a new indication in the prevention of postoperative nausea and vomiting in patients receiving general anesthesia for open abdominal surgery requiring overnight hospital stay.</brief_summary>
	<brief_title>2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)</brief_title>
	<detailed_description>The duration of treatment is 4 weeks.</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Postoperative Nausea and Vomiting</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>Patient is at least 18 years of age. Patient is scheduled to undergo open abdominal surgery requiring overnight hospital stay (24hour hospital stay after end of surgery). Patient is scheduled to receive general anesthesia. Patient is scheduled to receive postoperative medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>